Laryngeal Mask Airway for Surfactant Administration in Neonates: A Randomized, Controlled Trial

Area of Science:

• Neonatal Medicine
• Pediatric Critical Care
• Respiratory Physiology

Background:

• Respiratory distress syndrome (RDS) is a common condition in preterm infants.
• Continuous positive airway pressure (CPAP) is a standard treatment for RDS.
• Intubation and mechanical ventilation are often required for severe RDS, carrying significant risks.

Purpose of the Study:

• To evaluate the efficacy of surfactant administration via a laryngeal mask airway (LMA) in reducing intubation and mechanical ventilation rates in preterm infants with moderate RDS on CPAP.
• To compare the outcomes of LMA surfactant administration versus CPAP alone.

Main Methods:

• A prospective, multicenter, randomized controlled trial was conducted.
• 103 preterm infants (28-35 weeks gestation) with moderate RDS on CPAP were enrolled.
• Infants were randomized to receive surfactant via LMA or to continue CPAP alone (control group).

Main Results:

• The LMA group showed a significantly lower rate of intubation and mechanical ventilation (38%) compared to the control group (64%).
• The odds ratio for treatment failure was 0.30 (95% CI 0.13, 0.70).
• No serious adverse events were reported with LMA placement or surfactant administration.

Conclusions:

• Surfactant administration through an LMA is an effective method to decrease the need for intubation and mechanical ventilation in preterm neonates with moderate RDS.
• This LMA-based surfactant delivery method has the potential for significant clinical impact in diverse healthcare settings, including those with limited resources.